Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 1, 2013, Pages 11-27

  Tomicic, Maja T ^a   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cancer cell resistance; DSB repair; P53; Survivin; Topoisomerase I inhibitors; XIAP

Indexed keywords

BELOTECAN; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DIFLOMOTECAN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; EXATECAN; FLUOROURACIL; FOLINIC ACID; GIMATECAN; INDENOISOQUINOLINE DERIVATIVE; INDOLOCARBAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; IRINOTECAN; LURTOTECAN; PACLITAXEL; PHENANTHRIDINE DERIVATIVE; PLATINUM COMPLEX; PROTEIN P53; S 39625; SURVIVIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BIOLOGICAL FUNCTIONS; BLOOD TOXICITY; CANCER CELL; CANCER RESISTANCE; CLASSIFICATION; COLON METASTASIS; DIARRHEA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA TRANSCRIPTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME DEGRADATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GLIOMA; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; OVARY METASTASIS; P53 GENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECTUM CANCER; REVIEW; S PHASE CELL CYCLE CHECKPOINT; SENESCENCE; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TOP1 GENE; TUMOR CELL LINE; TUMOR GROWTH; UTERINE CERVIX CANCER; VOMITING;

ANIMALS; CAMPTOTHECIN; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; TOPOISOMERASE I INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

INTRACISTERNAL A-PARTICLES;

EID: 84867390244     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.09.002     Document Type: Review

References (275)

1. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev. 2009, 109:2894-2902.
2. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3:430-440.
3. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70:369-413.
4. Zhang H., Barcelo J.M., Lee B., Kohlhagen G., Zimonjic D.B., Popescu N.C., Pommier Y. Human mitochondrial topoisomerase I. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10608-10613.
5. Nitiss J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9:338-350.
6. Nitiss J.L. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 2009, 9:327-337.
7. Wang J.C. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys. 1998, 31:107-144.
8. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
9. Pommier Y., Pourquier P., Urasaki Y., Wu J., Laco G.S. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Updat. 1999, 2:307-318.
10. Wang J.C. Interaction between DNA and an Escherichia coli protein omega. J. Mol. Biol. 1971, 55:523-533.
11. D'Arpa P., Machlin P.S., Ratrie H., Rothfield N.F., Cleveland D.W., Earnshaw W.C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:2543-2547.
12. Wang H., Di Gate R.J., Seeman N.C. An RNA topoisomerase. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9477-9482.
13. Leppard J.B., Champoux J.J. Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma 2005, 114:75-85.
14. Stivers J.T., Harris T.K., Mildvan A.S. Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation. Biochemistry 1997, 36:5212-5222.
15. Stewart L., Redinbo M.R., Qiu X., Hol W.G., Champoux J.J. A model for the mechanism of human topoisomerase I. Science 1998, 279:1534-1541.
16. Koster D.A., Croquette V., Dekker C., Shuman S., Dekker N.H. Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature 2005, 434:671-674.
17. Alsner J., Svejstrup J.Q., Kjeldsen E., Sorensen B.S., Westergaard O. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function. J. Biol. Chem. 1992, 267:12408-12411.
18. Baker S.D., Wadkins R.M., Stewart C.F., Beck W.T., Danks M.K. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry 1995, 19:134-145.
19. Husain I., Mohler J.L., Seigler H.F., Besterman J.M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 1994, 54:539-546.
20. Kellner U., Heidebrecht H.J., Rudolph P., Biersack H., Buck F., Dakowski T., Wacker H.H., Domanowski M., Seidel A., Westergaard O., Parwaresch R. Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies. J. Histochem. Cytochem. 1997, 45:251-263.
21. Morham S.G., Kluckman K.D., Voulomanos N., Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol. Cell. Biol. 1996, 16:6804-6809.
22. Zhang C.X., Chen A.D., Gettel N.J., Hsieh T.S. Essential functions of DNA topoisomerase I in Drosophila melanogaster. Dev. Biol. 2000, 222:27-40.
23. Thrash C., Voelkel K., DiNardo S., Sternglanz R. Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity. J. Biol. Chem. 1984, 259:1375-1377.
24. Uemura T., Morikawa K., Yanagida M. The nucleotide sequence of the fission yeast DNA topoisomerase II gene: structural and functional relationships to other DNA topoisomerases. EMBO J. 1986, 5:2355-2361.
25. Eng W.K., Faucette L., Johnson R.K., Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 1988, 34:755-760.
26. Wall M.E., Wani M.C., Cook C.E. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88:3888-3890.
27. Horwitz M.S., Horwitz S.B. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. Biochem. Biophys. Res. Commun. 1971, 45:723-727.
28. Kessel D. Effects of camptothecin on RNA synthesis in leukemia L1210 cells. Biochim. Biophys. Acta 1971, 246:225-232.
29. Kessel D., Bosmann H.B., Lohr K. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochim. Biophys. Acta 1972, 269:210-216.
30. Spataro A., Kessel D. Studies on camptothecin-induced degradation and apparent reaggregation of DNA from L1210 cells. Biochem. Biophys. Res. Commun. 1972, 48:643-648.
31. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260:14873-14878.
32. Nitiss J., Wang J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:7501-7505.
33. Pommier Y., Barcelo J.M., Rao V.A., Sordet O., Jobson A.G., Thibaut L., Miao Z.H., Seiler J.A., Zhang H., Marchand C., Agama K., Nitiss J.L., Redon C. Repair of topoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol. 2006, 81:179-229.
34. Burke T.G., Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem. 1994, 37:40-46.
35. Teicher B.A. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem. Pharmacol. 2008, 75:1262-1271.
36. Urasaki Y., Laco G., Takebayashi Y., Bailly C., Kohlhagen G., Pommier Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res. 2001, 61:504-508.
37. Kurtzberg L.S., Battle T., Rouleau C., Bagley R.G., Agata N., Yao M., Schmid S., Roth S., Crawford J., Krumbholz R., Ewesuedo R., Yu X.J., Wang F., Lavoie E.J., Teicher B.A. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors. Mol. Cancer Ther. 2008, 7:3212-3222.
38. Antony S., Kohlhagen G., Agama K., Jayaraman M., Cao S., Durrani F.A., Rustum Y.M., Cushman M., Pommier Y. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol. Pharmacol. 2005, 67:523-530.
39. Antony S., Agama K.K., Miao Z.H., Takagi K., Wright M.H., Robles A.I., Varticovski L., Nagarajan M., Morrell A., Cushman M., Pommier Y. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res. 2007, 67:10397-10405.
40. Miao Z.H., Player A., Shankavaram U., Wang Y.H., Zimonjic D.B., Lorenzi P.L., Liao Z.Y., Liu H., Shimura T., Zhang H.L., Meng L.H., Zhang Y.W., Kawasaki E.S., Popescu N.C., Aladjem M.I., Goldstein D.J., Weinstein J.N., Pommier Y. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res. 2007, 67:8752-8761.
41. Covey J.M., Jaxel C., Kohn K.W., Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 1989, 49:5016-5022.
42. Jaxel C., Capranico G., Kerrigan D., Kohn K.W., Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 1991, 266:20418-20423.
43. Leteurtre F., Fesen M., Kohlhagen G., Kohn K.W., Pommier Y. Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry 1993, 32:8955-8962.
44. Tanizawa A., Kohn K.W., Kohlhagen G., Leteurtre F., Pommier Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 1995, 34:7200-7206.
45. Pourquier P., Pilon A.A., Kohlhagen G., Mazumder A., Sharma A., Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 1997, 272:26441-26447.
46. Pourquier P., Ueng L.M., Kohlhagen G., Mazumder A., Gupta M., Kohn K.W., Pommier Y. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem. 1997, 272:7792-7796.
47. Strumberg D., Pilon A.A., Smith M., Hickey R., Malkas L., Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell. Biol. 2000, 20:3977-3987.
48. Furuta T., Takemura H., Liao Z.Y., Aune G.J., Redon C., Sedelnikova O.A., Pilch D.R., Rogakou E.P., Celeste A., Chen H.T., Nussenzweig A., Aladjem M.I., Bonner W.M., Pommier Y. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 2003, 278:20303-20312.
49. Sordet O., Khan Q.A., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents 2003, 3:271-290.
50. Huang T.H., Chen H.C., Chou S.M., Yang Y.C., Fan J.R., Li T.K. Cellular processing determinants for the activation of damage signals in response to topoisomerase I-linked DNA breakage. Cell Res. 2010, 20:1060-1075.
51. Lin C.P., Ban Y., Lyu Y.L., Desai S.D., Liu L.F. A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. J. Biol. Chem. 2008, 283:21074-21083.
52. Sordet O., Redon C.E., Guirouilh-Barbat J., Smith S., Solier S., Douarre C., Conti C., Nakamura A.J., Das B.B., Nicolas E., Kohn K.W., Bonner W.M., Pommier Y. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep. 2009, 10:887-893.
53. Hertzberg R.P., Caranfa M.J., Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28:4629-4638.
54. Merino A., Madden K.R., Lane W.S., Champoux J.J., Reinberg D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature 1993, 365:227-232.
55. Darzynkiewicz Z., Bruno S., Del Bino G., Traganos F. The cell cycle effects of camptothecin. Ann. N. Y. Acad. Sci. 1996, 803:93-100.
56. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400:83-105.
57. Khobta A., Ferri F., Lotito L., Montecucco A., Rossi R., Capranico G. Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells. J. Mol. Biol. 2006, 357:127-138.
58. Capranico G., Ferri F., Fogli M.V., Russo A., Lotito L., Baranello L. The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I. Biochimie 2007, 89:482-489.
59. Sordet O., Larochelle S., Nicolas E., Stevens E.V., Zhang C., Shokat K.M., Fisher R.P., Pommier Y. Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. J. Mol. Biol. 2008, 381:540-549.
60. Desai S.D., Zhang H., Rodriguez-Bauman A., Yang J.M., Wu X., Gounder M.K., Rubin E.H., Liu L.F. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol. Cell. Biol. 2003, 23:2341-2350.
61. Ljungman M., Lane D.P. Transcription - guarding the genome by sensing DNA damage. Nat. Rev. Cancer 2004, 4:727-737.
62. Holm C., Covey J.M., Kerrigan D., Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 1989, 49:6365-6368.
63. Hsiang Y.H., Liu L.F., Wall M.E., Wani M.C., Nicholas A.W., Manikumar G., Kirschenbaum S., Silber R., Potmesil M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989, 49:4385-4389.
64. Morris E.J., Geller H.M. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J. Cell Biol. 1996, 134:757-770.
65. Goldwasser F., Shimizu T., Jackman J., Hoki Y., O'Connor P.M., Kohn K.W., Pommier Y. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 1996, 56:4430-4437.
66. Nitiss J.L., Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol. 1996, 50:1095-1102.
67. Zhou Y., Gwadry F.G., Reinhold W.C., Miller L.D., Smith L.H., Scherf U., Liu E.T., Kohn K.W., Pommier Y., Weinstein J.N. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 2002, 62:1688-1695.
68. Madden K.R., Champoux J.J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res. 1992, 52:525-532.
69. Burgess D.J., Doles J., Zender L., Xue W., Ma B., McCombie W.R., Hannon G.J., Lowe S.W., Hemann M.T. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9053-9058.
70. Liao Z., Robey R.W., Guirouilh-Barbat J., To K.K., Polgar O., Bates S.E., Pommier Y. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol. Pharmacol. 2008, 73:490-497.
71. McLeod H.L., Keith W.N. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br. J. Cancer 1996, 74:508-512.
72. Arnaud O., Boumendjel A., Geze A., Honorat M., Matera E.L., Guitton J., Stein W.D., Bates S.E., Falson P., Dumontet C., Di Pietro A., Payen L. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. Eur. J. Cancer 2011, 47:640-648.
73. Kubota E., Kataoka H., Tanaka M., Okamoto Y., Ebi M., Hirata Y., Murakami K., Mizoshita T., Shimura T., Mori Y.T., Tanida S., Kamiya T., Aoyama M., Asai K., Joh T. ERas enhances resistance to CPT-11 in gastric cancer. Anticancer. Res. 2011, 31:3353-3360.
74. Guo S., Zhang X., Gan L., Zhu C., Gan Y. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2). J. Pharm. Pharmacol. 2010, 62:973-984.
75. Zander S.A., Kersbergen A., van der Burg E., de Water N., van Tellingen O., Gunnarsdottir S., Jaspers J.E., Pajic M., Nygren A.O., Jonkers J., Borst P., Rottenberg S. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res. 2010, 70:1700-1710.
76. Rasheed Z.A., Rubin E.H. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003, 22:7296-7304.
77. Beidler D.R., Cheng Y.C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 1995, 47:907-914.
78. Desai S.D., Liu L.F., Vazquez-Abad D., D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 1997, 272:24159-24164.
79. Zhang H.F., Tomida A., Koshimizu R., Ogiso Y., Lei S., Tsuruo T. Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Cancer Res. 2004, 64:1114-1121.
80. Kerzendorfer C., Whibley A., Carpenter G., Outwin E., Chiang S.C., Turner G., Schwartz C., El-Khamisy S., Raymond F.L., O'Driscoll M. Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks. Hum. Mol. Genet. 2010, 19:1324-1334.
81. Cusack J.C., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J., Baldwin A.S. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001, 61:3535-3540.
82. Mao Y., Sun M., Desai S.D., Liu L.F. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4046-4051.
83. Muller S., Hoege C., Pyrowolakis G., Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2001, 2:202-210.
84. Mao Y., Mehl I.R., Muller M.T. Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1235-1240.
85. Rallabhandi P., Hashimoto K., Mo Y.Y., Beck W.T., Moitra P.K., D'Arpa P. Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin. J. Biol. Chem. 2002, 277:40020-40026.
86. Desai S.D., Li T.K., Rodriguez-Bauman A., Rubin E.H., Liu L.F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001, 61:5926-5932.
87. Squires S., Ryan A.J., Strutt H.L., Johnson R.T. Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res. 1993, 53:2012-2019.
88. El-Khamisy S.F., Katyal S., Patel P., Ju L., McKinnon P.J., Caldecott K.W. Synergistic decrease of DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin. DNA Repair (Amst) 2009, 8:760-766.
89. Hudson J.J., Chiang S.C., Wells O.S., Rookyard C., El-Khamisy S.F. SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair. Nat. Commun. 2012, 3:733.
90. Das B.B., Antony S., Gupta S., Dexheimer T.S., Redon C.E., Garfield S., Shiloh Y., Pommier Y. Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK. EMBO J. 2009, 28:3667-3680.
91. Chiang S.C., Carroll J., El-Khamisy S.F. TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage. Cell Cycle 2010, 9:588-595.
92. El-Khamisy S.F., Saifi G.M., Weinfeld M., Johansson F., Helleday T., Lupski J.R., Caldecott K.W. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005, 434:108-113.
93. Date H., Onodera O., Tanaka H., Iwabuchi K., Uekawa K., Igarashi S., Koike R., Hiroi T., Yuasa T., Awaya Y., Sakai T., Takahashi T., Nagatomo H., Sekijima Y., Kawachi I., Takiyama Y., Nishizawa M., Fukuhara N., Saito K., Sugano S., Tsuji S. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat. Genet. 2001, 29:184-188.
94. Moreira M.C., Barbot C., Tachi N., Kozuka N., Mendonca P., Barros J., Coutinho P., Sequeiros J., Koenig M. Homozygosity mapping of Portuguese and Japanese forms of ataxia-oculomotor apraxia to 9p13, and evidence for genetic heterogeneity. Am. J. Hum. Genet. 2001, 68:501-508.
95. Caldecott K.W. Single-strand break repair and genetic disease. Nat. Rev. Genet. 2008, 9:619-631.
96. Gueven N., Becherel O.J., Kijas A.W., Chen P., Howe O., Rudolph J.H., Gatti R., Date H., Onodera O., Taucher-Scholz G., Lavin M.F. Aprataxin, a novel protein that protects against genotoxic stress. Hum. Mol. Genet. 2004, 13:1081-1093.
97. Christmann M., Tomicic M.T., Gestrich C., Roos W.P., Bohr V.A., Kaina B. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation. DNA Repair (Amst) 2008, 7:1999-2009.
98. Tomicic M.T., Christmann M., Kaina B. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res. 2005, 65:8920-8926.
99. Sakasai R., Teraoka H., Tibbetts R.S. Proteasome inhibition suppresses DNA-dependent protein kinase activation caused by camptothecin. DNA Repair (Amst) 2010, 9:76-82.
100. Lin C.P., Ban Y., Lyu Y.L., Liu L.F. Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J. Biol. Chem. 2009, 284:28084-28092.
101. Tomicic M.T., Christmann M., Kaina B. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J. Pharmacol. Exp. Ther. 2010, 332:316-325.
102. Zhang Y.W., Regairaz M., Seiler J.A., Agama K.K., Doroshow J.H., Pommier Y. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 2011, 39:3607-3620.
103. Regairaz M., Zhang Y.W., Fu H., Agama K.K., Tata N., Agrawal S., Aladjem M.I., Pommier Y. Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J. Cell Biol. 2011, 195:739-749.
104. Ehmsen K.T., Heyer W.D. A junction branch point adjacent to a DNA backbone nick directs substrate cleavage by Saccharomyces cerevisiae Mus81-Mms4. Nucleic Acids Res. 2009, 37:2026-2036.
105. Vance J.R., Wilson T.E. Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13669-13674.
106. Liu C., Pouliot J.J., Nash H.A. The role of TDP1 from budding yeast in the repair of DNA damage. DNA Repair (Amst) 2004, 3:593-601.
107. Katyal S., el-Khamisy S.F., Russell H.R., Li Y., Ju L., Caldecott K.W., McKinnon P.J. TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. EMBO J. 2007, 26:4720-4731.
108. Hubert L., Lin Y., Dion V., Wilson J.H. Topoisomerase 1 and single-strand break repair modulate transcription-induced CAG repeat contraction in human cells. Mol. Cell. Biol. 2011, 31:3105-3112.
109. Plo I., Liao Z.Y., Barcelo J.M., Kohlhagen G., Caldecott K.W., Weinfeld M., Pommier Y. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) 2003, 2:1087-1100.
110. Zhou T., Lee J.W., Tatavarthi H., Lupski J.R., Valerie K., Povirk L.F. Deficiency in 3'-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). Nucleic Acids Res. 2005, 33:289-297.
111. Interthal H., Chen H.J., Champoux J.J. Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J. Biol. Chem. 2005, 280:36518-36528.
112. Interthal H., Chen H.J., Kehl-Fie T.E., Zotzmann J., Leppard J.B., Champoux J.J. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J. 2005, 24:2224-2233.
113. Miao Z.H., Agama K., Sordet O., Povirk L., Kohn K.W., Pommier Y. Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) 2006, 5:1489-1494.
114. Perego P., Cossa G., Tinelli S., Corna E., Carenini N., Gatti L., De Cesare M., Ciusani E., Zunino F., Luison E., Canevari S., Zaffaroni N., Beretta G.L. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem. Pharmacol. 2012, 83:27-36.
115. Gupta E., Toppmeyer D., Zamek R., Much J., Ibrahim N., Goodin S., Kane M., Aisner J., Li X.G., Haluska P., Medina M., Cornfield A., Vyas V.N., Giovanella E.B., Saleem A., Rubin E. Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy. Cancer Ther. 1998, 1:292-301.
116. Rubin E., Wood V., Bharti A., Trites D., Lynch C., Hurwitz S., Bartel S., Levy S., Rosowsky A., Toppmeyer D., Kufe D. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res. 1995, 1:269-276.
117. Saleem A., Edwards T.K., Rasheed Z., Rubin E.H. Mechanisms of resistance to camptothecins. Ann. N. Y. Acad. Sci. 2000, 922:46-55.
118. Lenz H.J. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev. 2003, 29(Suppl. 1):41-48.
119. Shao R.G., Cao C.X., Zhang H., Kohn K.W., Wold M.S., Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 1999, 18:1397-1406.
120. Tian X., Chen G., Xing H., Weng D., Guo Y., Ma D. The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa. Oncol. Rep. 2007, 18:927-932.
121. Darroudi F., Wiegant W., Meijers M., Friedl A.A., van der Burg M., Fomina J., van Dongen J.J., van Gent D.C., Zdzienicka M.Z. Role of Artemis in DSB repair and guarding chromosomal stability following exposure to ionizing radiation at different stages of cell cycle. Mutat. Res. 2007, 615:111-124.
122. Katsube T., Mori M., Tsuji H., Shiomi T., Shiomi N., Onoda M. Differences in sensitivity to DNA-damaging agents between XRCC4- and Artemis-deficient human cells. J. Radiat. Res. 2011, 52:415-424.
123. Biard D.S. Untangling the relationships between DNA repair pathways by silencing more than 20 DNA repair genes in human stable clones. Nucleic Acids Res. 2007, 35:3535-3550.
124. Yaneva M., Li H., Marple T., Hasty P. Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor. Nucleic Acids Res. 2005, 33:5320-5330.
125. Adachi N., So S., Koyama H. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage. J. Biol. Chem. 2004, 279:37343-37348.
126. Otsuki M., Seki M., Kawabe Y., Inoue E., Dong Y.P., Abe T., Kato G., Yoshimura A., Tada S., Enomoto T. WRN counteracts the NHEJ pathway upon camptothecin exposure. Biochem. Biophys. Res. Commun. 2007, 355:477-482.
127. Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H., Fesik S., Zhang H. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 2003, 278:21767-21773.
128. Yin M.B., Hapke G., Wu J., Azrak R.G., Frank C., Wrzosek C., Rustum Y.M. Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350. Biochem. Biophys. Res. Commun. 2002, 295:435-444.
129. Cliby W.A., Lewis K.A., Lilly K.K., Kaufmann S.H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 2002, 277:1599-1606.
130. Hapke G., Yin M.B., Wu J., Frank C., Rustum Y.M. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38. Int. J. Oncol. 2002, 21:1059-1066.
131. Flatten K., Dai N.T., Vroman B.T., Loegering D., Erlichman C., Karnitz L.M., Kaufmann S.H. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J. Biol. Chem. 2005, 280:14349-14355.
132. Wang J.L., Wang X., Wang H., Iliakis G., Wang Y. CHK1-regulated S-phase checkpoint response reduces camptothecin cytotoxicity. Cell Cycle 2002, 1:267-272.
133. Shao R.G., Cao C.X., Shimizu T., O'Connor P.M., Kohn K.W., Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 1997, 57:4029-4035.
134. Xiao Z., Xue J., Sowin T.J., Rosenberg S.H., Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005, 24:1403-1411.
135. Schwarz J.K., Lovly C.M., Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res. 2003, 1:598-609.
136. Chaturvedi P., Eng W.K., Zhu Y., Mattern M.R., Mishra R., Hurle M.R., Zhang X., Annan R.S., Lu Q., Faucette L.F., Scott G.F., Li X., Carr S.A., Johnson R.K., Winkler J.D., Zhou B.B. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999, 18:4047-4054.
137. Ward I.M., Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J. Biol. Chem. 2001, 276:47759-47762.
138. Zuco V., Benedetti V., Zunino F. ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968. Cancer Lett. 2010, 292:186-196.
139. Agner J., Falck J., Lukas J., Bartek J. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp. Cell Res. 2005, 302:162-169.
140. Smith P.J., Makinson T.A., Watson J.V. Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I. Int. J. Radiat. Biol. 1989, 55:217-231.
141. Jones N.J., Ellard S., Waters R., Parry E.M. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells. Carcinogenesis 1993, 14:2487-2494.
142. Johnson R.T., Gotoh E., Mullinger A.M., Ryan A.J., Shiloh Y., Ziv Y., Squires S. Targeting double-strand breaks to replicating DNA identifies a subpathway of DSB repair that is defective in ataxia-telangiectasia cells. Biochem. Biophys. Res. Commun. 1999, 261:317-325.
143. Johnson M.A., Bryant P.E., Jones N.J. Isolation of camptothecin-sensitive chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group. Mutagenesis 2000, 15:367-374.
144. Reaper P.M., Griffiths M.R., Long J.M., Charrier J.D., Maccormick S., Charlton P.A., Golec J.M., Pollard J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7:428-430.
145. O'Driscoll M., Dobyns W.B., van Hagen J.M., Jeggo P.A. Cellular and clinical impact of haploinsufficiency for genes involved in ATR signaling. Am. J. Hum. Genet. 2007, 81:77-86.
146. O'Driscoll M. Mouse models for ATR deficiency. DNA Repair (Amst) 2009, 8:1333-1337.
147. Nghiem P., Park P.K., Kim Y., Vaziri C., Schreiber S.L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9092-9097.
148. Cortez D., Guntuku S., Qin J., Elledge S.J. ATR and ATRIP: partners in checkpoint signaling. Science 2001, 294:1713-1716.
149. Wilsker D., Bunz F. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol. Cancer Ther. 2007, 6:1406-1413.
150. Flatt P.M., Tang L.J., Scatena C.D., Szak S.T., Pietenpol J.A. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol. Cell. Biol. 2000, 20:4210-4223.
151. Magrini R., Bhonde M.R., Hanski M.L., Notter M., Scherubl H., Boland C.R., Zeitz M., Hanski C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer 2002, 101:23-31.
152. Wang Y., Zhu S., Cloughesy T.F., Liau L.M., Mischel P.S. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004, 23:1283-1290.
153. Furuta T., Hayward R.L., Meng L.H., Takemura H., Aune G.J., Bonner W.M., Aladjem M.I., Kohn K.W., Pommier Y. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 2006, 25:2839-2849.
154. Chang B.D., Broude E.V., Dokmanovic M., Zhu H., Ruth A., Xuan Y., Kandel E.S., Lausch E., Christov K., Roninson I.B. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999, 59:3761-3767.
155. te Poele R., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002, 62:1876-1883.
156. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., Lowe S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
157. Bhonde M.R., Hanski M.L., Notter M., Gillissen B.F., Daniel P.T., Zeitz M., Hanski C. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 2006, 25:165-175.
158. Andreassen P.R., Lohez O.D., Lacroix F.B., Margolis R.L. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol. Biol. Cell 2001, 12:1315-1328.
159. Bhonde M.R., Hanski M.L., Budczies J., Cao M., Gillissen B., Moorthy D., Simonetta F., Scherubl H., Truss M., Hagemeier C., Mewes H.W., Daniel P.T., Zeitz M., Hanski C. DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis. J. Biol. Chem. 2006, 281:8675-8685.
160. Morandi E., Severini C., Quercioli D., D'Ario G., Perdichizzi S., Capri M., Farruggia G., Mascolo M.G., Horn W., Vaccari M., Serra R., Colacci A., Silingardi P. Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines. Mol. Cancer 2008, 7:66.
161. Slichenmyer W.J., Nelson W.G., Slebos R.J., Kastan M.B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 1993, 53:4164-4168.
162. Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N., Krajewski S., Reed J.C., von Deimling A., Dichgans J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer 1998, 79:640-644.
163. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999, 59:1391-1399.
164. Nieves-Neira W., Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int. J. Cancer 1999, 82:396-404.
165. McDonald A.C., Brown R. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br. J. Cancer 1998, 78:745-751.
166. Schmidt F., Rieger J., Wischhusen J., Naumann U., Weller M. Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Eur. J. Pharmacol. 2001, 412:21-25.
167. Gobert C., Bracco L., Rossi F., Olivier M., Tazi J., Lavelle F., Larsen A.K., Riou J.F. Modulation of DNA topoisomerase I activity by p53. Biochemistry 1996, 35:5778-5786.
168. Soe K., Grosse F. p53 stimulates human topoisomerase I activity by modulating its DNA binding. Nucleic Acids Res. 2003, 31:6585-6592.
169. Stephan H., Grosse F., Soe K. Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro. Nucleic Acids Res. 2002, 30:5087-5093.
170. Winter S., Weller M. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. J. Pharmacol. Exp. Ther. 1998, 286:1374-1382.
171. Dubrez L., Goldwasser F., Genne P., Pommier Y., Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995, 9:1013-1024.
172. Solary E., Dubrez L., Eymin B., Bertrand R., Pommier Y. Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors. Bull. Cancer 1996, 83:205-212.
173. Shimizu T., Pommier Y. Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia 1997, 11:1238-1244.
174. Gupta M., Fan S., Zhan Q., Kohn K.W., O'Connor P.M., Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res. 1997, 3:1653-1660.
175. Blumenthal R.D., Leone E., Goldenberg D.M., Rodriguez M., Modrak D. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Int. J. Cancer 2004, 108:293-300.
176. Davis P.L., Shaiu W.L., Scott G.L., Iglehart J.D., Hsieh T.S., Marks J.R. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer. Res. 1998, 18:2919-2932.
177. te Poele R.H., Joel S.P. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br. J. Cancer 1999, 81:1285-1293.
178. Abal M., Bras-Goncalves R., Judde J.G., Fsihi H., De Cremoux P., Louvard D., Magdelenat H., Robine S., Poupon M.F. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 2004, 23:1737-1744.
179. Oggionni M., Pilotti S., Suardi S., Ditto A., Luoni C., Mariani L., Scambia G., Fanfani F., Zunino F. p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma. Oncology 2005, 69:154-158.
180. Daoud S.S., Munson P.J., Reinhold W., Young L., Prabhu V.V., Yu Q., LaRose J., Kohn K.W., Weinstein J.N., Pommier Y. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res. 2003, 63:2782-2793.
181. Roos W.P., Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 2006, 12:440-450.
182. Kaufmann T., Strasser A., Jost P.J. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 2012, 19:42-50.
183. Ciusani E., Perego P., Carenini N., Corna E., Facchinetti F., Boiardi A., Salmaggi A., Zunino F. Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors. Biochem. Pharmacol. 2002, 63:881-887.
184. Ferreira C.G., Span S.W., Peters G.J., Kruyt F.A., Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 2000, 60:7133-7141.
185. Ferreira C.G., Tolis C., Span S.W., Peters G.J., van Lopik T., Kummer A.J., Pinedo H.M., Giaccone G. Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin. Cancer Res. 2000, 6:203-212.
186. Dejosez M., Ramp U., Mahotka C., Krieg A., Walczak H., Gabbert H.E., Gerharz C.D. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ. 2000, 7:1127-1136.
187. Song J.H., Song D.K., Pyrzynska B., Petruk K.C., Van Meir E.G., Hao C. TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol. 2003, 13:539-553.
188. Wang S., El-Deiry W.S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15095-15100.
189. Monks A., Harris E.D., Vaigro-Wolff A., Hose C.D., Connelly J.W., Sausville E.A. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest. New Drugs 2000, 18:95-107.
190. Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
191. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
192. Galvan V., Kurakin A.V., Bredesen D.E. Interaction of checkpoint kinase 1 and the X-linked inhibitor of apoptosis during mitosis. FEBS Lett. 2004, 558:57-62.
193. Jin H.S., Lee D.H., Kim D.H., Chung J.H., Lee S.J., Lee T.H. cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res. 2009, 69:1782-1791.
194. Wu Z.H., Wong E.T., Shi Y., Niu J., Chen Z., Miyamoto S., Tergaonkar V. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol. Cell 2010, 40:75-86.
195. Bruno T., Iezzi S., De Nicola F., Di Padova M., Desantis A., Scarsella M., Di Certo M.G., Leonetti C., Floridi A., Passananti C., Fanciulli M. Che-1 activates XIAP expression in response to DNA damage. Cell Death Differ. 2008, 15:515-520.
196. Bruno T., De Nicola F., Iezzi S., Lecis D., D'Angelo C., Di Padova M., Corbi N., Dimiziani L., Zannini L., Jekimovs C., Scarsella M., Porrello A., Chersi A., Crescenzi M., Leonetti C., Khanna K.K., Soddu S., Floridi A., Passananti C., Delia D., Fanciulli M. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell 2006, 10:473-486.
197. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
198. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3:401-410.
199. Kanwar J.R., Kamalapuram S.K., Kanwar R.K. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today 2011, 16:485-494.
200. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., Chung C.W., Jung Y.K., Oh B.H. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123.
201. Arora V., Cheung H.H., Plenchette S., Micali O.C., Liston P., Korneluk R.G. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J. Biol. Chem. 2007, 282:26202-26209.
202. Liu T., Brouha B., Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004, 23:39-48.
203. Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., Choo K.H. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 2000, 10:1319-1328.
204. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
205. Skoufias D.A., Mollinari C., Lacroix F.B., Margolis R.L. Human survivin is a kinetochore-associated passenger protein. J. Cell Biol. 2000, 151:1575-1582.
206. Lens S.M., Wolthuis R.M., Klompmaker R., Kauw J., Agami R., Brummelkamp T., Kops G., Medema R.H. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J. 2003, 22:2934-2947.
207. Yang D., Welm A., Bishop J.M. Cell division and cell survival in the absence of survivin. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15100-15105.
208. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837.
209. Yamamoto H., Ngan C.Y., Monden M. Cancer cells survive with survivin. Cancer Sci. 2008, 99:1709-1714.
210. Borgne A., Versteege I., Mahe M., Studeny A., Leonce S., Naime I., Rodriguez M., Hickman J.A., Meijer L., Golsteyn R.M. Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment. Oncogene 2006, 25:7361-7372.
211. Tse A.N., Schwartz G.K. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 2004, 64:6635-6644.
212. Vogel C., Kienitz A., Muller R., Bastians H. The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. J. Biol. Chem. 2005, 280:4025-4028.
213. Vogel C., Hager C., Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007, 67:339-345.
214. Reichert S., Rodel C., Mirsch J., Harter P.N., Tomicic M.T., Mittelbronn M., Kaina B., Rodel F. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother. Oncol. 2011, 101:51-58.
215. Lladser A., Sanhueza C., Kiessling R., Quest A.F. Is survivin the potential Achilles' heel of cancer?. Adv. Cancer Res. 2011, 111:1-37.
216. Sato A., Ito K., Asano T., Sumitomo M., Asano T., Hayakawa M. Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake. Int. J. Oncol. 2007, 30:695-700.
217. Sato A., Ito K., Asano T., Sumitomo M., Asano T., Hayakawa M. Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan. Int. J. Oncol. 2008, 32:171-176.
218. Pennati M., Binda M., De Cesare M., Pratesi G., Folini M., Citti L., Daidone M.G., Zunino F., Zaffaroni N. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004, 25:1129-1136.
219. Griffith T.S., Kemp T.J. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother. Pharmacol. 2003, 52:175-184.
220. Ravi R., Jain A.J., Schulick R.D., Pham V., Prouser T.S., Allen H., Mayer E.G., Yu H., Pardoll D.M., Ashkenazi A., Bedi A. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 2004, 64:9105-9114.
221. Mizutani K., Matsumoto K., Hasegawa N., Deguchi T., Nozawa Y. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. Exp. Oncol. 2006, 28:209-215.
222. Zhang B., Luo Y., Weng Q., He Q., Lu W., Yang B. CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901. Invest. New Drugs 2008, 26:517-524.
223. Li Y., Rory Goodwin C., Sang Y., Rosen E.M., Laterra J., Xia S. Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. Anticancer Drugs 2009, 20:770-778.
224. Tun C., Guo W., Nguyen H., Yun B., Libby R.T., Morrison R.S., Garden G.A. Activation of the extrinsic caspase pathway in cultured cortical neurons requires p53-mediated down-regulation of the X-linked inhibitor of apoptosis protein to induce apoptosis. J. Neurochem. 2007, 102:1206-1219.
225. Yamaguchi Y., Shiraki K., Fuke H., Inoue T., Miyashita K., Yamanaka Y., Saitou Y., Sugimoto K., Nakano T. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol. Rep. 2005, 14:1311-1316.
226. Bevins R.L., Zimmer S.G. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res. 2005, 65:6957-6966.
227. Arnt C.R., Chiorean M.V., Heldebrant M.P., Gores G.J., Kaufmann S.H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 2002, 277:44236-44243.
228. Minderman H., Conroy J.M., O'Loughlin K.L., McQuaid D., Quinn P., Li S., Pendyala L., Nowak N.J., Baer M.R. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol. Cancer Ther. 2005, 4:885-900.
229. Takigawa N., Vaziri S.A., Grabowski D.R., Chikamori K., Rybicki L.R., Bukowski R.M., Ganapathi M.K., Ganapathi R., Mekhail T. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms. Anticancer. Res. 2006, 26:1869-1876.
230. Liston P., Fong W.G., Kelly N.L., Toji S., Miyazaki T., Conte D., Tamai K., Craig C.G., McBurney M.W., Korneluk R.G. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat. Cell Biol. 2001, 3:128-133.
231. Plenchette S., Cheung H.H., Fong W.G., LaCasse E.C., Korneluk R.G. The role of XAF1 in cancer. Curr. Opin. Investig. Drugs 2007, 8:469-476.
232. Dohi T., Okada K., Xia F., Wilford C.E., Samuel T., Welsh K., Marusawa H., Zou H., Armstrong R., Matsuzawa S., Salvesen G.S., Reed J.C., Altieri D.C. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 2004, 279:34087-34090.
233. Zhang W., Guo Z., Jiang B., Niu L., Xia G., Wang X., Cheng T., Zhang Y., Wang J. Identification of a functional p53 responsive element within the promoter of XAF1 gene in gastrointestinal cancer cells. Int. J. Oncol. 2010, 36:1031-1037.
234. Zou B., Chim C.S., Pang R., Zeng H., Dai Y., Zhang R., Lam C.S., Tan V.P., Hung I.F., Lan H.Y., Wong B.C. XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification. Mol. Carcinog. 2012, 51:422-432.
235. Yang Y., Fang S., Jensen J.P., Weissman A.M., Ashwell J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000, 288:874-877.
236. Nakhaei P., Sun Q., Solis M., Mesplede T., Bonneil E., Paz S., Lin R., Hiscott J. IkappaB kinase epsilon-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis. J. Virol. 2012, 86:726-737.
237. Franklin E.E., Robertson J.D. Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis. Biochem. J. 2007, 405:115-122.
238. Krumschnabel G., Sohm B., Bock F., Manzl C., Villunger A. The enigma of caspase-2: the laymen's view. Cell Death Differ. 2009, 16:195-207.
239. Guo Y., Srinivasula S.M., Druilhe A., Fernandes-Alnemri T., Alnemri E.S. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J. Biol. Chem. 2002, 277:13430-13437.
240. Slee E.A., Keogh S.A., Martin S.J. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ. 2000, 7:556-565.
241. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
242. Holt S.V., Brookes K.E., Dive C., Makin G.W. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol. Rep. 2011, 25:1177-1181.
243. Carter B.Z., Mak D.H., Morris S.J., Borthakur G., Estey E., Byrd A.L., Konopleva M., Kantarjian H., Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 2011, 16:67-74.
244. Carter B.Z., Mak D.H., Schober W.D., Cabreira-Hansen M., Beran M., McQueen T., Chen W., Andreeff M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006, 107:1555-1563.
245. Sah N.K., Munshi A., Hobbs M., Carter B.Z., Andreeff M., Meyn R.E. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:852-859.
246. Capalbo G., Dittmann K., Weiss C., Reichert S., Hausmann E., Rodel C., Rodel F. Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77:226-234.
247. Rodel F., Reichert S., Sprenger T., Gaipl U.S., Mirsch J., Liersch T., Fulda S., Rodel C. The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr. Med. Chem. 2012, 18:191-199.
248. Vermeulen C., Bertocci B., Begg A.C., Vens C. Ionizing radiation sensitivity of DNA polymerase lambda-deficient cells. Radiat. Res. 2007, 168:683-688.
249. Shih S.J., Erbele T., Chen A.Y. Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells. Cancer Res. 2005, 65:9194-9199.
250. Rao V.A., Fan A.M., Meng L., Doe C.F., North P.S., Hickson I.D., Pommier Y. Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage. Mol. Cell. Biol. 2005, 25:8925-8937.
251. Rahden-Staron I., Szumilo M., Grosicka E., Kraakman van der Zwet M., Zdzienicka M.Z. Defective Brca2 influences topoisomerase I activity in mammalian cells. Acta Biochim. Pol. 2003, 50:139-144.
252. Marple T., Kim T.M., Hasty P. Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination. Mutat. Res. 2006, 602:110-120.
253. James E., Waldron-Lynch M.G., Saif M.W. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 2009, 20:634-638.
254. Nakamura K., Kogame T., Oshiumi H., Shinohara A., Sumitomo Y., Agama K., Pommier Y., Tsutsui K.M., Tsutsui K., Hartsuiker E., Ogi T., Takeda S., Taniguchi Y. Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet. 2011, 6:e1000828.
255. Sonoda E., Zhao G.Y., Kohzaki M., Dhar P.K., Kikuchi K., Redon C., Pilch D.R., Bonner W.M., Nakano A., Watanabe M., Nakayama T., Takeda S., Takami Y. Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair. DNA Repair (Amst) 2007, 6:280-292.
256. Wang X., Hu B., Weiss R.S., Wang Y. The effect of Hus1 on ionizing radiation sensitivity is associated with homologous recombination repair but is independent of nonhomologous end-joining. Oncogene 2006, 25:1980-1983.
257. Nomura Y., Adachi N., Koyama H. Human Mus81 and FANCB independently contribute to repair of DNA damage during replication. Genes Cells 2007, 12:1111-1122.
258. Wang X., Takenaka K., Takeda S. PTIP promotes DNA double-strand break repair through homologous recombination. Genes Cells 2010, 15:243-254.
259. Ambrosini G., Seelman S.L., Qin L.X., Schwartz G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res. 2008, 68:2312-2320.
260. Godthelp B.C., Wiegant W.W., van Duijn-Goedhart A., Scharer O.D., van Buul P.P., Kanaar R., Zdzienicka M.Z. Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Nucleic Acids Res. 2002, 30:2172-2182.
261. Saberi A., Nakahara M., Sale J.E., Kikuchi K., Arakawa H., Buerstedde J.M., Yamamoto K., Takeda S., Sonoda E. The 9-1-1 DNA clamp is required for immunoglobulin gene conversion. Mol. Cell. Biol. 2008, 28:6113-6122.
262. Shiomi N., Mori M., Tsuji H., Imai T., Inoue H., Tateishi S., Yamaizumi M., Shiomi T. Human RAD18 is involved in S phase-specific single-strand break repair without PCNA monoubiquitination. Nucleic Acids Res. 2007, 35:e9.
263. Huang J., Huen M.S., Kim H., Leung C.C., Glover J.N., Yu X., Chen J. RAD18 transmits DNA damage signalling to elicit homologous recombination repair. Nat. Cell Biol. 2009, 11:592-603.
264. Saberi A., Hochegger H., Szuts D., Lan L., Yasui A., Sale J.E., Taniguchi Y., Murakawa Y., Zeng W., Yokomori K., Helleday T., Teraoka H., Arakawa H., Buerstedde J.M., Takeda S. RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair. Mol. Cell. Biol. 2007, 27:2562-2571.
265. Sharma S., Brosh R.M. Human RECQ1 is a DNA damage responsive protein required for genotoxic stress resistance and suppression of sister chromatid exchanges. PLoS One 2007, 2:e1297.
266. Hu Y., Lu X., Zhou G., Barnes E.L., Luo G. Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment. Mol. Biol. Cell 2009, 20:114-123.
267. Wang H., Zhao A., Chen L., Zhong X., Liao J., Gao M., Cai M., Lee D.H., Li J., Chowdhury D., Yang Y.G., Pfeifer G.P., Yen Y., Xu X. Human RIF1 encodes an anti-apoptotic factor required for DNA repair. Carcinogenesis 2009, 30:1314-1319.
268. Hinz J.M., Helleday T., Meuth M. Reduced apoptotic response to camptothecin in CHO cells deficient in XRCC3. Carcinogenesis 2003, 24:249-253.
269. Caldecott K., Jeggo P. Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat. Res. 1991, 255:111-121.
270. Thacker J., Ganesh A.N. DNA-break repair, radioresistance of DNA synthesis, and camptothecin sensitivity in the radiation-sensitive irs mutants: comparisons to ataxia-telangiectasia cells. Mutat. Res. 1990, 235:49-58.
271. Lebel M., Leder P. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13097-13102.
272. Poot M., Gollahon K.A., Rabinovitch P.S. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum. Genet. 1999, 104:10-14.
273. Pichierri P., Franchitto A., Mosesso P., Palitti F. Werner's syndrome cell lines are hypersensitive to camptothecin-induced chromosomal damage. Mutat. Res. 2000, 456:45-57.
274. Rodriguez R., Hansen L.T., Phear G., Scorah J., Spang-Thomsen M., Cox A., Helleday T., Meuth M. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of Mre11. Clin. Cancer Res. 2008, 14:5476-5483.
275. Johnson M.A., Jones N.J. The isolation and genetic analysis of V79-derived etoposide sensitive Chinese hamster cell mutants: two new complementation groups of etoposide sensitive mutants. Mutat. Res. 1999, 435:271-282.